Capricor Earnings Reports

Capricor Therapeutics posted a net loss of $24.6 million in Q3 2025 with no reported revenue, while operating expenses rose sharply year-over-year. The company ended the quarter with $98.6 million in cash, projecting sufficient funds through Q4 2026.

In Q2 2025, Capricor Therapeutics posted a net loss of $25.9M or $0.57 per share, driven by increased operating expenses and no reported revenue. Cash balance at the end of the quarter was $122.8M, expected to fund operations into Q4 2026.

Capricor Therapeutics reported a net loss of $24.4 million for the first quarter of 2025, compared to a net loss of $9.8 million in the same period last year, with no revenue generated. The company's cash balance was approximately $144.8 million, expected to support operations into 2027. Key updates include the ongoing priority review of its BLA for deramiocel by the FDA, with a PDUFA date of August 31, 2025, and the planned initiation of a Phase 1 clinical trial for its StealthX™ exosome vaccine in Q3 2025.

Capricor Therapeutics posted a net loss for Q4 2024, with decreased revenue and increased operating expenses. The company maintained a strong cash position and continues advancing its pipeline and regulatory efforts.

Capricor Therapeutics reported a net loss of $12.6 million, or $0.38 per share, for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled approximately $85.0 million as of September 30, 2024. They commenced the submission of BLA and significantly strengthened their balance sheet.

Capricor Therapeutics reported revenue of $4.0 million and a net loss of $11.0 million, or $0.35 per share, for the second quarter of 2024. The company is focused on advancing its lead asset, deramiocel, and securing a partnership in Europe.

Capricor Therapeutics reported revenue of $4.9 million and a net loss of $9.8 million for the first quarter of 2024. The company received a $10 million milestone payment under its U.S. Distribution and Commercialization Agreement with Nippon Shinyaku.

Capricor Therapeutics reported Q4 2023 revenue of $12.1 million, a net loss of $0.8 million, or $0.02 per share. The company's cash, cash equivalents, and marketable securities totaled approximately $39.5 million as of December 31, 2023.

Capricor Therapeutics reported revenue of $6.2 million and a net loss of $6.4 million, or $0.25 per share, for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled approximately $28.5 million as of September 30, 2023. Targeted enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy was completed.

Capricor Therapeutics reported revenue of $3.9 million for the second quarter of 2023, primarily from the recognition of an upfront payment related to a commercialization agreement. The company's net loss for the quarter was $7.4 million, or $0.29 per share. They believe that their current financial resources will be sufficient to cover expenses through the third quarter of 2024.

Capricor Therapeutics reported revenue of $3.0 million for the first quarter of 2023, compared to zero for the same period in 2022. The company's net loss was approximately $7.8 million, or $0.31 per share, for the first quarter of 2023, which is similar to the net loss of approximately $7.8 million, or $0.32 per share, for the first quarter of 2022.

Capricor Therapeutics reported fourth-quarter revenue of $1.0 million, a net loss of $7.7 million, or $0.31 per share, and cash, cash equivalents, and marketable securities totaling $41.4 million as of December 31, 2022.

Capricor Therapeutics reported revenue of $1.6 million and a net loss of $6.4 million, or $0.26 per share for the third quarter of 2022. As of September 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $46.6 million.

Capricor Therapeutics reported a net loss of $7.1 million, or $0.29 per share, for the second quarter of 2022. As of June 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $51.4 million.

Capricor Therapeutics reported a net loss of $7.8 million, or $0.32 per share, for the first quarter of 2022. The company's cash and cash equivalents totaled approximately $58.3 million as of March 31, 2022, bolstered by a $30 million upfront payment from Nippon Shinyaku for the commercialization and distribution of CAP-1002.

Capricor Therapeutics reported a net loss of $6.2 million, or $0.26 per share, for the fourth quarter of 2021. As of December 31, 2021, the company's cash and cash equivalents totaled $34.9 million.

Capricor Therapeutics reported a net loss of approximately $3.9 million, or $0.17 per share, for the three months ended September 30, 2021. The company's cash and cash equivalents totaled approximately $40.8 million as of September 30, 2021.

Capricor Therapeutics reported revenue of $200,000 and a net loss of $4.7 million, or $0.21 per share, for the three months ended June 30, 2021. The company's cash and cash equivalents balance totaled approximately $38.1 million as of June 30, 2021.

Capricor Therapeutics reported a net loss of $5.2 million, or $0.23 per share, for the first quarter of 2021. As of March 31, 2021, the Company’s cash and cash equivalents totaled approximately $41.9 million.

Capricor Therapeutics reported a net loss of $4.2 million, or $0.21 per share, for the fourth quarter of 2020, compared to a net loss of $1.5 million, or $0.34 per share, for the fourth quarter of 2019. As of December 31, 2020, the Company’s cash, cash equivalents and marketable securities totaled approximately $32.7 million.

Capricor Therapeutics reported a net loss of $3.9 million, or $0.20 per share, for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled approximately $35.3 million as of September 30, 2020.

Capricor Therapeutics reported a net loss of $3.5 million, or $0.23 per share, for the second quarter of 2020. As of June 30, 2020, the Company’s cash, cash equivalents and marketable securities totaled approximately $36.3 million.

Capricor Therapeutics reported a net loss of $2.1 million for the first quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $13.2 million as of March 31, 2020. They also made advances in their DMD and COVID-19 pipeline development.

Capricor Therapeutics reported a net loss of $1.5 million, or $0.34 per share, for the fourth quarter of 2019, compared to a net loss of $3.3 million, or $1.05 per share, for the fourth quarter of 2018. As of December 31, 2019, the Company’s cash, cash equivalents and marketable securities totaled approximately $9.9 million.